A new drug went on the market, creating many medical firsts in China.
This is the first time that a heavyweight new drug in the world has been listed in China. For the first time, the pharmaceutical industry in China participated in clinical trials in accordance with the internationally accepted patent licensing cooperation model and obtained the regional production and sales rights of new drugs. This is a great event in the medical field in China. Top experts, hospitals and doctors in the domestic digestive tract field have taken the initiative to intervene. They are excited for the first time that the medical profession in China participated in the "Top Competition" of digestive tract research in the world. This new drug is called eprazole. According to the practice of the pharmaceutical industry, new drugs with a sales potential of 654.38 billion US dollars in the international mainstream market are called "blockbusters". Ample is recognized as a well-deserved "blockbuster". The State Administration of Pharmaceutical Products of China has approved the production and sale of iprazole in China. Livzon Group has the exclusive patent right to produce and sell the drug in China (including Hongkong and Macau), and it is in full production.